Desonide
Desowen, Tridesilon, Verdeso (desonide) is a small molecule pharmaceutical. Desonide was first approved as Tridesilon on 1982-01-01. It is used to treat facial dermatoses, foot dermatoses, hand dermatoses, inflammation, and leg dermatoses amongst others in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Desowen, Verdeso (generic drugs available since 1988-06-15, discontinued: Desonate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetic acid
+
glacial
+
Desonide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIDESILON | Bayer | N-017914 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| desonate | New Drug Application | 2010-11-08 |
| desonide | ANDA | 2023-03-03 |
| desowen | ANDA, New Drug Application | 2019-01-28 |
| tridesilon cream | New Drug Application | 2016-04-21 |
| verdeso | New Drug Application | 2020-04-29 |
Agency Specific
FDA
EMA
No data
ATC Codes
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB08: Desonide
— D07B: Corticosteroids, combinations with antiseptics
— D07BB: Corticosteroids, moderately potent, combinations with antiseptics
— D07BB02: Desonide and antiseptics
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA11: Desonide
HCPCS
Code | Description |
|---|---|
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg |
| J7627 | Budesonide, inhalation solution, compounded product, administered through dme, unit dose form, up to 0.5 mg |
| J7633 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligram |
| J7634 | Budesonide, inhalation solution, compounded product, administered through dme, concentrated form, per 0.25 milligram |
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DESONIDE |
| INN | desonide |
| Description | Desonide is triamcinolone acetonide with hydrogen instead of the fluorine substituent at position 9. A corticosteroid anti-inflammatory, it is used topically as a cream, ointment or lotion for the treatment of various skin disorders. It has a role as an anti-inflammatory drug. It is an 11beta-hydroxy steroid, a 21-hydroxy steroid, a 20-oxo steroid, a corticosteroid, a cyclic ketal, a 3-oxo-Delta(1),Delta(4)-steroid and a primary alpha-hydroxy ketone. |
| Classification | Small molecule |
| Drug class | topical steroids (acetal derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1 |
Identifiers
| PDB | — |
| CAS-ID | 638-94-8 |
| RxCUI | 3254 |
| ChEMBL ID | CHEMBL1201109 |
| ChEBI ID | 204734 |
| PubChem CID | 5311066 |
| DrugBank | DB01260 |
| UNII ID | J280872D1O (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 349 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more